Author: Sarah Dolman and Maggie Pickard

Recon takes an analytical look behind select developments in healthcare

An auto- or allo- future for cell therapy?

Download a PDF of this article here. Ex vivo gene-therapies have been a game-changer in clinical for aggressive hematologic cancers. These products can effectively cure patients who otherwise had very low chance of survival beyond 5 -years.  However, making these products is exceptionally complex and the drugs are priced accordingly (from $370,000 to over $2.5M). While few patients receive these treatments today, clinical development could lead to a much broader population. If 1 in 20 newly diagnosed cancers were optimally treated with these high-price therapies, the cost to health-payers could

Read More